90 citations,
December 2007 in “Current Oncology” Non-hormonal treatments should be used first for sexual dysfunction in postmenopausal breast cancer patients on aromatase inhibitors, with hormones as a second option.
34 citations,
November 2013 in “Breast Cancer Research and Treatment” Aromatase inhibitor therapy for breast cancer increases the risk of hair loss and thinning.
18 citations,
August 2019 in “Clinical breast cancer” Local hormonal treatment for vulvovaginal atrophy is likely safe for women with estrogen receptor-positive breast cancer on aromatase inhibitors.
1 citations,
September 2020 in “Pediatric Dermatology” Two teenage boys lost hair after taking a drug for growth, which was not a known side effect for kids.
7 citations,
March 2011 in “Expert Opinion on Drug Safety” Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.
67 citations,
April 2018 in “JAMA Dermatology” Hair loss from hormone therapy in breast cancer patients can be improved with minoxidil treatment.
9 citations,
April 2018 in “JAMA Dermatology” Topical minoxidil improves hair loss in 80% of women with breast cancer undergoing endocrine therapy.
7 citations,
May 2016 in “SpringerPlus” Some breast cancer patients on hormone therapy experience hair loss, and treatments like certain topical inhibitors and supplements may help without harming their cancer prognosis.
37 citations,
September 2018 in “The Journal of Clinical Endocrinology and Metabolism” Intravaginal testosterone cream improves sexual satisfaction and reduces vaginal discomfort in postmenopausal women on breast cancer treatment without affecting hormone levels.
7 citations,
September 2023 in “Cancer Treatment Reviews” Managing side effects of endocrine therapy is crucial to improve adherence and survival in breast cancer patients.
Certain drugs can worsen hair loss in people prone to androgenetic alopecia.
77 citations,
April 2009 in “British Journal of Dermatology” Aromatase gene variation may increase female hair loss risk.
January 2023 in “Mastology” Hormone therapy for breast cancer often leads to sexual issues like vaginal dryness and decreased libido.
251 citations,
October 2014 in “The Journal of Clinical Endocrinology & Metabolism” The guidelines advise against using testosterone and DHEA in women for most conditions due to safety and effectiveness concerns, but suggest considering testosterone for postmenopausal women with low sexual desire.
75 citations,
February 2016 in “The Journal of Sexual Medicine” Androgens play a role in female sexual function, and testosterone therapy can help women with low sexual desire, but more research is needed on treatments and long-term safety.
32 citations,
March 2019 in “Climacteric” Premature ovarian insufficiency (POI) can harm women's sexual health, and they may benefit from hormone therapy and counseling.
32 citations,
January 2018 in “American Journal of Clinical Dermatology” Hormone therapy affects hair growth in transgender individuals, with testosterone potentially causing hair loss in trans men and estrogen reducing facial/body hair in trans women; treatment options vary.
28 citations,
May 2013 in “The Journal of Steroid Biochemistry and Molecular Biology” Testosterone therapy can improve sexual desire and function in postmenopausal women but should be used cautiously and not based solely on testosterone levels.
22 citations,
January 2015 in “The Cochrane library” DHEA may help with sexual function when used intravaginally by menopausal women but is similar to hormone therapy in other aspects and might cause more side effects like acne and hair loss.
1 citations,
January 2018 in “Springer eBooks” The document concludes that scalp cooling and treatments like minoxidil can help manage hair loss from cancer therapy.
March 2023 in “JAAD case reports” 
22 citations,
November 2018 in “Breast Cancer Research and Treatment” The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.
4 citations,
October 2018 in “Asia-Pacific Journal of Clinical Oncology” CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
3 citations,
September 2014 in “Journal of obstetrics and gynaecology Canada” Menopause often leads to lower sexual desire and discomfort during sex, but treatment should be personalized and only if it bothers the woman.
November 2021 in “Austin therapeutics” Current treatments for hair loss from chemotherapy are limited, but new methods are being researched.
451 citations,
March 2005 in “Endocrine Reviews” The enzyme steroid sulfatase is linked to breast cancer and other conditions, and inhibitors are being developed for treatment.
48 citations,
September 2013 in “Oncologist” Endocrine therapies for cancer significantly increase the risk of hair loss.
February 2024 in “PloS one” Nutraceuticals that promote hair growth do not reduce tamoxifen's effectiveness in breast cancer treatment.
11 citations,
November 2012 in “Seminars in Cutaneous Medicine and Surgery” Genetic factors affect hair loss, and molecular testing may help predict, diagnose, and treat it.
February 2023 in “IntechOpen eBooks” Testosterone replacement therapy helps manage deficiency and has various methods, but requires careful monitoring to avoid side effects.